A new immunotherapy eliminated – for the first time – [amazon_textlink asin=’B07568XPRJ’ text=’breast cancer’ template=’ProductLink’ store=’mdsh-20′ marketplace=’US’ link_id=’bde27cb8-697f-11e8-a6fe-efb7d0e3ec76′], as well as metastatic tumors in a woman who was in the final stage of the disease and her doctors, gave her only three months of life.
Two years later, there is no trace of cancer in her body. This treatment is experimental and is currently tested with absolute success in only one patient. But in the future, it can revolutionize the treatment of all cancers, according to scientists.
The treatment consists of introducing millions of immune cells into the patient’s body, helping the body to fight the tumors. Researchers at the US National Cancer Institute, headed by Dr. Steven Rosenberg, have made the relevant publication in the medical journal “Nature Medicine,” according to BBC Guardian. Indeed, the research team also participated in the Greek origin, Nikolaos Zacharakis.
49-year-old patient Judy Perkins living in Florida had metastatic breast cancer that could not be treated with routine treatments. She had reached the point of having in her liver tumors in tennis ball size, as well as other volumes elsewhere in her body. Approximately two weeks after the experimental treatment, tumors completely disappeared and have not recurred since.
Treatment is based on a “live drug” made by the patient’s immune system cells. “We are talking about the most advanced personalized treatment that exists,” Rosenberg said.
After the genetic analysis of the patient’s tumors to identify the specific cancer mutations, selected lymphocytes (TIL) were taken from her blood, cultured in large quantities in the laboratory (about 90 billion) and then reintroduced into her body along with a drug (pembrolizumab) that helps the immune system [amazon_textlink asin=’B00J13I2MA’ text=’attack cancer’ template=’ProductLink’ store=’mdsh-20′ marketplace=’US’ link_id=’f9c1a323-697f-11e8-8740-590266ea83f3′] cells.
However, more tests with a larger number of patients are needed to confirm the efficacy of the new treatment before being used more widely in clinical practice.